Danish Hospital conducts a clinical trial of Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy
Rigshospitalet, Denmark is commencing recruitment for the clinical trial of the Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy.
The condition is Pancreas Cancer.
A new clinical trial is recruiting patients in the following locations: Denmark.
The trial officially began on the February 2021 and is planned to complete on August 1, 2022.
Perioperative immunologic signatures can predict the risk of postoperative complications.
The population that can be enrolled into this study includes:
- Adult patients scheduled for PD on the suspicion of pancreatic cancer excluding patients receiving immunomodulating treatment 1 month properatively and/or autoimmune diseases and patients non-cenacerous cystic lessions.
- Patients scheduled for simultaneous procedures on major arterial blood vessels, and/or adjacent organs (spleen, liver) are also not included.
- Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory instability hindering procedure completion and/or concomitant surgery on major arterial blood vessels, spleen, or liver, are excluded post-inclusion and will not be part of the primary analysis.
- Patients eligible for inclusion will be identified before their appointment.
Patients with the following pathologies:
- Bilirubin >100 µmol/ltr.
- Patients receiving immunomodulating treatment 1 month properatively and/or autoimmune diseases and patients non-cenacerous cystic lessions.
- Patients scheduled for simultaneous procedures on major arterial blood vessels, and/or adjacent organs (spleen, liver).
- Inoperable patients, for instance, due to carcinosis, circulatory/ventilatory instability hindering procedure completion and/or concomitant surgery on major arterial blood vessels, spleen, or liver, are excluded post-inclusion and will not be part of the primary analysis.
- Ongoing treatment with glucocortocoid, anti-tnf-alpha etc.
- Patients diagnosed with rheumatological diseases, IBD or chronic infection (eg. HIV)
are excluded from participation.
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04774198
